Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 26kWORD 21k
11 June 2019
Answer given by Ms Bieńkowska on behalf of the European Commission
Question reference: E-001741/2019

1. The European Parliament Resolution concerns a draft Commission Implementing Decision granting an authorisation for certain uses of chromium trioxide(1). The draft decision proposed to grant an authorisation as it concluded that the conditions for granting an authorisation in Article 60(4) of Regulation (EC) No 1907/2006 were met in this case (i.e. that the socioeconomic benefits from the use of the substance outweigh the risk to human health, and there are no suitable alternatives).

The draft decision proposed different review periods for different uses, taking into account concerns regarding the appropriateness and effectiveness of the risk management measures in place for the different uses, the expected social and economic consequences in the supply chain resulting from a refusal of an authorisation, the time necessary to implement possible alternatives, and related scientific uncertainties due to the broad scope of the uses applied for.

2. The socioeconomic impacts of refusing an authorisation were taken into account when assessing the socioeconomic benefits of a granted authorisation. They were also considered when proposing the review period, together with the quality of the risk control measures and the assessment of alternatives. If companies do not have suitable alternatives beyond the end of the review period for their uses, the authorisation holders can submit a review report with a view to enable their downstream users to continue using the substance beyond that date.

3. Although the Commission considers that it has not exceeded its implementing powers, it is now reviewing the draft decision also taking into account the issues raised in the European Parliament’s Resolution. Once the review is completed, the Commission will inform the European Parliament of its decision on whether it intends to maintain or amend the draft decision(2).

(1)Lanxess GmbH and others.
(2)In accordance with Article 11 of Regulation (EU) 182/2011.

Last updated: 13 June 2019Legal notice